FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes

The Food and Drug Administration on August 28, 2026, expanded the approved use of Mounjaro, Eli Lilly’s tirzepatide injection, to include lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them. Eli Lilly announced the approval the same day, and the news was widely covered by financial, medical and trade outlets within 24 hours.

Mounjaro isn’t new. The FDA first approved the drug on May 13, 2022, to improve blood-sugar control in adults with type 2 diabetes as an adjunct to diet and exercise, then later expanded its use to children 10 and older. This week’s decision adds a cardiovascular indication to that existing label rather than approving a new drug.

Key facts

Approval date: August 28, 2026
Drug: Mounjaro (tirzepatide), made by Eli Lilly
New use: Lowering the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with type 2 diabetes who are at high risk
Trial: SURPASS-CVOT — about 13,300 patients at roughly 640 sites in 30 countries, followed for a median of about four years
Result: Major adverse cardiovascular events occurred in 12.2% of tirzepatide patients vs. 13.1% of dulaglutide patients (hazard ratio 0.92)
Comparator: Tested head-to-head against dulaglutide (Trulicity), not a placebo
Not covered: Zepbound, Lilly’s identically-dosed tirzepatide brand for weight management, does not carry this indication

Timeline

January 2020 — FDA approves Ozempic’s first cardiovascular indication, for adults with type 2 diabetes and known heart disease.
May 13, 2022 — FDA first approves Mounjaro to improve blood-sugar control in adults with type 2 diabetes as an adjunct to diet and exercise.
March 2024 — FDA approves Wegovy’s cardiovascular indication, for adults with overweight or obesity and established cardiovascular disease.
January 2025 — FDA expands Ozempic’s indication to cover chronic kidney disease and cardiovascular death.
December 17, 2025 — SURPASS-CVOT topline results are published in the New England Journal of Medicine.
August 28, 2026 — FDA approves Mounjaro’s cardiovascular indication in adults with type 2 diabetes.

What the approval is based on

The label expansion rests on SURPASS-CVOT, an event-driven, randomized, double-blind Phase 3 cardiovascular outcomes trial that enrolled roughly 13,300 adults with type 2 diabetes and known cardiovascular disease at about 640 sites in 30 countries. Rather than testing tirzepatide against a placebo, Lilly compared it head-to-head against its own older GLP-1 drug, dulaglutide, sold as Trulicity — a drug that already has an established cardiovascular benefit of its own. Patients were followed for a median of roughly four years, and topline results were first published in the New England Journal of Medicine on December 17, 2025, ahead of this week’s FDA decision.

“We set a higher bar by testing Mounjaro against a GLP-1 medicine with proven cardiovascular benefit,” said Kenneth Custer, an Eli Lilly executive vice president who leads the company’s cardiometabolic health business.

What the trial actually showed

This is the part worth reading carefully. The trial’s main measure — a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke, a combination doctors call MACE, for major adverse cardiovascular events — occurred in 12.2% of patients on tirzepatide versus 13.1% of patients on dulaglutide. That works out to a hazard ratio of 0.92, or roughly an 8% lower rate.

That result cleared the trial’s pre-set bar for non-inferiority (P=0.003 for non-inferiority) — a statistical test asking only whether tirzepatide worked at least as well as dulaglutide. It did not clear the separate, higher bar for superiority (P=0.09 for superiority) — the test that would have shown tirzepatide working statistically better than dulaglutide. The confidence interval around that 8% figure ran from 0.83 to 1.01, a range that includes the possibility of no real difference at all. In plain terms, the trial shows tirzepatide worked at least as well as an already-effective heart drug; it did not prove tirzepatide worked better.

One secondary finding, not part of what the FDA’s cardiovascular indication itself rests on, did clear a statistical bar on its own: patients on tirzepatide had a 16% lower rate of death from any cause than patients on dulaglutide, with a confidence interval (0.75 to 0.94) that does not include the possibility of no difference.

Custer, in the same Lilly statement, described the approval as a “proven way” to lower cardiovascular risk and said it adds to Mounjaro’s existing benefits in blood-sugar control and weight. That is company language that reaches further than the trial’s own statistics prove. The approval rests on the non-inferiority result above, not on a finding that tirzepatide beat dulaglutide.

Who the new label covers

The indication applies to adults with type 2 diabetes who are at high risk for cardiovascular events — in the trial, that meant people who already had known cardiovascular disease. It does not extend to Zepbound, Lilly’s identically-dosed tirzepatide brand sold for chronic weight management and obstructive sleep apnea. Zepbound’s approvals are separate, and none of them include a cardiovascular indication.

How it compares with Ozempic and Wegovy

Mounjaro isn’t the first diabetes or weight-loss drug to carry an FDA cardiovascular indication. Novo Nordisk’s semaglutide already holds two: Ozempic, for adults with type 2 diabetes and known heart disease, since January 2020 (expanded in January 2025 to cover chronic kidney disease and cardiovascular death); and Wegovy, for adults with overweight or obesity and established cardiovascular disease, since March 2024. What’s new here is the drug class — Mounjaro works on two gut-hormone receptors (GIP and GLP-1) instead of one, making it the first dual-acting drug of its kind to earn a cardiovascular indication.

A different outcome in Europe

The European Medicines Agency reviewed a similar application and did not grant Mounjaro a separate cardiovascular indication. It agreed only to add the SURPASS-CVOT trial data to the drug’s existing product information for patients in the EU — a narrower outcome than the FDA reached from the same trial.

Safety profile stays the same

The cardiovascular results didn’t surface a new safety concern.

Most common side effects (typically mild to moderate, most common while a patient’s dose is being increased):

Nausea
Diarrhea
Reduced appetite
Vomiting
Constipation
Indigestion
Abdominal pain

Existing warnings that still apply:

Pancreatitis
Low blood sugar
Allergic reactions
Gallbladder problems
Dehydration-related kidney issues

Why it matters for Lilly

Mounjaro is Lilly’s top revenue driver, bringing in $9.9 billion in revenue in the second quarter of 2026 alone, up 91% from a year earlier. A cardiovascular indication broadens the eligible prescribing population and puts Lilly in more direct competition with Novo Nordisk’s semaglutide brands, which already carry similar cardiovascular indications.

Financial outlets described Lilly shares as gaining modestly after the announcement, though reports differed on the size of the move and did not establish a single precise percentage.